← Back to Stock Screener← Stock Screener

ZYBERNO

Stock Report

Updated Jun 9, 2026

Eagle Pharmaceuticals, Inc. (EGRX)

Healthcare • Over The Counter

$0.60

Professional Investment Analysis

ZYBERNO SCORE →

Is it a great business? Is it getting better?

37.0/100

WEAK BUSINESS

Eagle Pharmaceuticals, Inc. (EGRX) scores 37/100 — weak fundamentals with mixed indicators requiring careful analysis before acting.

📊 How is the Zyberno Score calculated? +

The Zyberno Score answers one question: "Is this a quality business worth owning?" It's a 0-100 investment grade that evaluates business fundamentals across four critical dimensions, based on principles from Warren Buffett, Benjamin Graham, Peter Lynch, and Charlie Munger.

The 4 Core Categories (25 points each):

1. PROFITABILITY (25 pts)

Metrics: ROE, ROIC, Net Margin, Operating Margin
Thresholds: ROE >20% excellent • ROIC >20% excellent • Net Margin >20% excellent • Operating Margin >25% excellent

2. FINANCIAL STRENGTH (25 pts)

Metrics: Debt-to-Equity, Current Ratio, Interest Coverage, Altman Z-Score
Thresholds: D/E <0.3 excellent • Current Ratio >2.5 excellent • Interest Coverage >10x excellent • Altman Z >3.0 safe

3. CASH FLOW QUALITY (25 pts)

Metrics: Free Cash Flow, OCF vs Net Income, FCF Margin
Thresholds: Positive & growing FCF excellent • OCF/NI >1.2x excellent (cash earnings exceed accounting)

4. GROWTH & CONSISTENCY (25 pts)

Metrics: Revenue Growth, Net Income Growth, FCF Growth, Piotroski F-Score
Thresholds: Growth via log-linear regression • Piotroski 8-9 excellent, 6-7 good

Score Interpretation:

75-100

GREAT BUSINESS

65-74

GOOD BUSINESS

50-64

AVERAGE BUSINESS

30-49

WEAK BUSINESS

0-29

POOR BUSINESS

→ View full EGRX quality analysis & detailed breakdown

VALUATION SIGNAL

N/A (Requires more data)

Requires fair value calculation and current price data

💰 How is Margin of Safety calculated? +

Margin of Safety measures how much discount or premium you're paying relative to a stock's intrinsic value. It's Benjamin Graham's core principle: the larger the margin, the lower your downside risk.

Formula: (Intrinsic Value − Current Price) ÷ Intrinsic Value × 100%

How We Calculate Intrinsic Value (DCF Method):

Step 1: Calculate current Owner Earnings (OCF − Maintenance CapEx)

Step 2: Calculate company-specific growth rate using log-linear regression on 16 quarters of Owner Earnings

Step 3: Project 10 years forward using the calculated growth rate

Step 4: Discount each year's cash flow to present value using 10% discount rate

Step 5: Calculate terminal value using 3% perpetual growth rate

Step 6: Sum all discounted cash flows = Intrinsic Value

What The Percentages Mean:

+50% or more

EXCELLENT — Very undervalued

+25% to +50%

GOOD — Attractive discount

0% to +25%

FAIR — Reasonable value

0% to -25%

CAUTION — Slight premium

-25% or worse

POOR — Overvalued

"Price is what you pay, value is what you get." — Warren Buffett

→ View full EGRX valuation analysis · → View full EGRX Brina Gap analysis

📈 How is Brina Gap calculated? +

Brina Gap measures the difference between the growth a business can fundamentally sustain and the growth the market is already pricing in.

Formula: Fundamental Growth Rate − Market-Implied Growth Rate

The Two Components:

Fundamental Growth Rate = ROIC × Reinvestment Rate

What the business can sustainably grow at based on how much it reinvests and what return it earns on that capital. Grounded in historical financials.

Market-Implied Growth Rate = Reverse DCF

The growth rate the current Enterprise Value implicitly assumes. Calculated by back-solving a 10-year DCF model (10% WACC, 3% terminal growth) until the present value of projected cash flows equals EV.

What The Gap Means:

Gap > +5% Market Underestimates — potential upside

+2% to +5% Slight Underestimate

-2% to +2% Fairly Priced — market consensus matches fundamentals

-5% to -2% Slight Overestimate

Gap < -5% Market Overestimates — price embeds optimism fundamentals don't support

A positive gap (market underestimates) combined with a positive Margin of Safety is the strongest combined signal — the business is both cheap historically and forward economics are stronger than the price suggests.

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (5.0%)

Debt-to-Equity (Solvency Risk):EXCELLENT (0.02x)

Operating Margin (Operational Efficiency):GOOD (15.9%)

Return on Capital (Capital Efficiency):CRITICAL (4.9%)

📊 Valuation Trilogy

Three interconnected metrics for complete valuation analysis

Click any metric for full methodology and detailed analysis

Zyberno's Verdict

Eagle Pharmaceuticals, Inc. (EGRX) stock report — Zyberno Score 37/100 (WEAK BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, EGRX generated -$4.77M in Owner Earnings. Capital was deployed as follows: $94.00K invested in capital expenditures. Reinvestment rate: -54.1%.

DIVISION I: EXECUTIVE SUMMARY

A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.60

Market Cap:$2.62M

Valuation Multiples (4)

P/E Ratio:

0.38x

📊 Click to view full EGRX P/E analysis →

P/B Ratio:0.02x

P/S Ratio:0.02x

Peg Ratio:-999.00x

Enterprise Metrics (2)

Enterprise Value:-$182.83K

Ev Ebitda Ratio:0.00x

B. Profitability Assessment

Return Metrics (5)

ROE:

5.0%

📊 Click to view full EGRX ROE analysis →

ROA:3.0%

Roic:

4.9%

📊 Click to view full EGRX ROIC analysis →

Reinvestment Rate:-54.1%

Fundamental Growth Rate (g):-2.7%

Margin Analysis (3)

Operating Margin Ttm:15.9%

Net Margin Ttm:4.6%

Ebitda Margin:16.0%

TTM Performance (3)

Gross Margin Ttm:71.6%

Operating Margin Ttm:15.9%

Net Margin Ttm:4.6%

Yield Metrics (2)

Earnings Yield:$260.92

Dividend Yield:0.0%

C. Log-Linear Regression Growth Trends

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):21.6%

Earnings Growth (Linear) (1)

Net Income Growth Rate (Linear):-11.3%

Cash Flow Growth (Linear) (2)

Free Cash Flow Growth Rate (Linear):26.9%

Operating Cash Flow Growth Rate (Linear):2.2%

Operating Growth (Linear) (1)

Operating Income Growth Rate (Linear):2.4%

D. Financial Stability

Liquidity Ratios (3)

Current Ratio:2.16x

Quick Ratio:1.67x

Cash Ratio:0.18x

Leverage Analysis (3)

Debt To Equity Ttm:0.02x

Debt-to-Equity Ratio:0.02x

Debt To Ebitda:0.30x

Coverage Ratios (2)

Interest Coverage Ratio:15.25x

Times Interest Earned:15.25

Capital Structure (4)

Working Capital:100,620,000.00

Cash And Cash Equivalents:15,354,000.00

Long Term Debt:$4.26M

Net Debt:-$2.80M

DIVISION II: FINANCIAL STATEMENTS ANALYSIS

A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $257.55M

Linear Growth: 21.6%

📊 Click to view full EGRX Revenue analysis & methodology →

Cost Of Revenue Ttm:$73.27M

Profitability Breakdown (2)

Gross profit TTM: $184.28M

Linear Growth: 29.5%

📊 Click to view full EGRX Gross Profit analysis & methodology →

Operating income TTM: $41.01M

Linear Growth: 2.4%

📊 Click to view full EGRX Operating Income analysis & methodology →

Bottom Line Performance (3)

Net income TTM: $11.95M

Linear Growth: -11.3%

📊 Click to view full EGRX Net Income analysis & methodology →

Income Before Tax:$9.30M

Ebitda Ttm:41,205,000.00

Operating Expenses (5)

Operating Expenses:54,342,000.00

R And D Expense:9,833,000.00

Sga Expense:27,651,000.00

Income Tax Expense:$4.13M

Interest Expense:1,448,000.00

Expense Ratios (3)

R And D To Revenue Percentage:15.2%

Sga To Revenue Percentage:42.8%

Ebitda Margin:16.0%

B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$404.82M

Current Assets:$187.25M

Ppe Net:1,013,000.00

Goodwill:45,033,000.00

Intangible Assets:$107.41M

Liability Structure (4)

Total Liabilities:152,782,000.00

Current Liabilities:86,630,000.00

Long Term Debt:$4.26M

Short Term Debt:$8.30M

Equity & Capital (3)

Equity:$252.04M

Retained Earnings:$122.42M

Common Stock:18,000.00

Working Capital Items (3)

Accounts Receivable:115,140,000.00

Inventory:42,482,000.00

Accounts Payable:15,843,000.00

Special Items (2)

Contract Liabilities:3,046,000.00

Stock Based Compensation:4,192,000.00

C. Cash Flow Analysis

Operating Activities (2)

Operating cash flow TTM: -$22.46M

Linear Growth: 2.2%

Free cash flow TTM: -$4.77M

Linear Growth: 26.9%

📊 Click to view full EGRX Free Cash Flow analysis & methodology →

Investment Activities (2)

Investing Cash Flow:-$12.56M

Capital Expenditures Ttm:-94,000.00

Financing Activities (3)

Financing Cash Flow:$6.24M

Dividends Paid Ttm:0.00

Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00

Long Term Debt Issuance:$0.00

Long Term Debt Repayments:$2.50M

Non-Cash Items (1)

Depreciation Amortization Ttm:25,940,000.00

DIVISION III: OPERATIONAL METRICS

A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):0.86

Eps diluted TTM: $0.89

Linear Growth: -9.8%

📊 Click to view full EGRX EPS analysis & methodology →

Earnings Per Share Ttm:$0.83

Revenue & Cash Per Share (2)

Sales Per Share Ttm:10.00

Operating Cash Flow Per Share:-$2.57

Book Value & Capital (2)

Book Value Per Share:$19.25

Cash Per Share:1.17

Dividend Policy (1)

Dividend Payout Ratio:0.00x

B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.33x

Working Capital Turnover Ttm:1.30x

Receivables Management (2)

Receivables Turnover Ttm:1.14x

Days Sales Outstanding Ttm:320.93

Inventory Management (2)

Inventory Turnover Ttm:0.80x

Days Inventory Outstanding Ttm:453.95

Payables & Cash Cycle (2)

Days Payable Outstanding:169.29

Cash Conversion Cycle:605.58

C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00

Quality Score:145.00

Market Metrics (2)

Beta:0.00x

Volatility Category:unknown

DIVISION IV: INVESTMENT ANALYSIS

A. Value Investment Framework

Owner Earnings Analysis (1)

-$4.77M

Damodaran Growth Analysis (2)

Reinvestment Rate:-54.1%

Fundamental Growth Rate (g):-2.7%

B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (3)

Revenue Growth Rate (Linear):21.6%

Net Income Growth Rate (Linear):-11.3%

Operating Income Growth Rate (Linear):2.4%

Cash Flow Growth Rates (2)

Free Cash Flow Growth Rate (Linear):26.9%

Operating Cash Flow Growth Rate (Linear):2.2%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):29.5%

Book Value Growth Rate (Linear):13.4%

C. Company Profile & Context

Corporate Information (6)

Symbol:EGRX

Company Name:Eagle Pharmaceuticals, Inc.

Sector:Healthcare

Industry:Pharmaceuticals

Exchange:Over The Counter

Country:Unknown

Market Classification (3)

Market Cap Category:N/A

Price Category:penny

Volume Category:N/A

Share Structure (3)

Shares Outstanding:13.09M

Shares Outstanding Basic:13.09M

Shares Outstanding Diluted:13.15M

Data Processing Info (3)

Processing Version:v3.0

Last Updated:2026-06-09 11:23:11 UTC

Data Timestamp:2026-03-28T15:06:53.595002